Strides Pharma Science Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals

Quality Assessment: Mixed Signals Amidst Long-Term Concerns

Strides Pharma’s quality metrics present a complex picture. While the company has delivered very positive quarterly results for Q3 FY25-26, including a remarkable 133.64% growth in net profit and a 128.0% increase in PAT to ₹204.91 crores, its long-term fundamental strength remains weak. The average Return on Capital Employed (ROCE) over recent years stands at a modest 7.27%, which is below industry expectations for sustainable growth.

Moreover, the company’s net sales have grown at an annualised rate of 9.32% over the past five years, with operating profit expanding at 15.52%. These figures, while positive, suggest moderate growth compared to peers in the pharmaceuticals sector. A notable concern is the company’s high Debt to EBITDA ratio of 6.58 times, indicating a relatively low ability to service debt, which could pose risks in volatile market conditions.

Adding to the risk profile, 30.6% of promoter shares are pledged, which historically tends to exert downward pressure on stock prices during market downturns. This factor weighs heavily on the quality grade, contributing to the cautious stance despite operational improvements.

Valuation: Attractive Yet Not Without Caveats

From a valuation standpoint, Strides Pharma appears reasonably priced. The company’s ROCE for the half-year period has improved to 16.05%, and it currently trades at an enterprise value to capital employed ratio of 2.3, which is considered attractive relative to its peers. The stock is trading at a discount compared to the average historical valuations of comparable companies in the pharmaceuticals and biotechnology sector.

Despite this, the stock’s recent price performance shows some volatility. The current price stands at ₹895.75, down 1.03% on the day, with a 52-week high of ₹1,024.90 and a low of ₹551.00. Over the past year, the stock has generated a return of 39.90%, significantly outperforming the Sensex, which declined by 1.65% over the same period. However, profits have fallen by 8.5% in the last year, signalling some underlying operational challenges that investors should consider.

Financial Trend: Strong Quarterly Performance Contrasted by Long-Term Challenges

Financially, Strides Pharma has demonstrated very positive momentum in recent quarters. The company has reported positive results for ten consecutive quarters, with operating profit to interest coverage reaching a high of 5.44 times in the latest quarter. This indicates improved operational efficiency and a better capacity to meet interest obligations in the short term.

However, the long-term financial trend is less encouraging. The company’s net sales and operating profit growth rates over five years, while positive, are not robust enough to inspire confidence in sustained expansion. Additionally, the high debt burden and pledged promoter shares introduce financial vulnerabilities that could limit future growth prospects.

Comparing returns, Strides Pharma has outperformed the BSE500 index in each of the last three annual periods, delivering cumulative returns of 574.74% over three years and 142.79% over five years. This track record of consistent returns is a positive indicator but must be weighed against the company’s fundamental and technical challenges.

Technicals: Downgrade Driven by Bearish Momentum

The primary catalyst for the downgrade to a Sell rating is the deterioration in technical indicators. The technical trend has shifted from mildly bullish to mildly bearish, signalling caution for short- to medium-term investors. Key technical metrics reveal a mixed but predominantly negative outlook:

• MACD (Moving Average Convergence Divergence) is mildly bearish on both weekly and monthly charts.
• RSI (Relative Strength Index) shows no signal on the weekly chart but is bearish on the monthly timeframe.
• Bollinger Bands remain mildly bullish weekly and bullish monthly, indicating some price support but limited upside momentum.
• Moving averages on the daily chart are mildly bearish, reinforcing the short-term downtrend.
• KST (Know Sure Thing) oscillator is bearish weekly and mildly bearish monthly, confirming weakening momentum.
• Dow Theory shows no clear trend weekly but mildly bullish monthly, suggesting some longer-term support.
• On-Balance Volume (OBV) is mildly bullish on both weekly and monthly charts, indicating some accumulation despite price weakness.

These mixed signals, with a tilt towards bearishness, have prompted a reassessment of the stock’s technical grade, leading to the downgrade from Hold to Sell. The current market price of ₹895.75, down from the previous close of ₹905.10, reflects this cautious sentiment.

Comparative Returns and Market Context

Strides Pharma’s recent returns relative to the Sensex further illustrate its volatile performance. Over the past week, the stock declined by 1.72%, slightly outperforming the Sensex’s 2.40% fall. Over one month, however, the stock gained 3.07% while the Sensex dropped 10.05%, and year-to-date returns are marginally negative at -0.73% compared to the Sensex’s -12.92%. These figures highlight the stock’s resilience in a challenging market environment but also underscore the need for caution given the technical signals.

Conclusion: A Cautious Stance Amid Contrasting Signals

In summary, Strides Pharma Science Ltd’s downgrade to a Sell rating by MarketsMOJO reflects a careful balancing of strong recent financial results and attractive valuation against deteriorating technical indicators and underlying fundamental risks. The company’s weak long-term growth metrics, high debt levels, and significant promoter share pledging weigh heavily on its quality and financial trend scores.

While the stock has outperformed market benchmarks over multiple timeframes and maintains an attractive valuation relative to peers, the shift to a mildly bearish technical trend signals potential near-term headwinds. Investors should consider these factors carefully and monitor the stock’s technical developments alongside its financial performance before making investment decisions.

Strides Pharma remains a stock with mixed attributes: strong operational momentum and consistent returns on one hand, and financial leverage and technical weakness on the other. This nuanced profile justifies the current Sell rating and suggests a cautious approach for investors seeking exposure to the Pharmaceuticals & Biotechnology sector.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →